S-1 and CPT-11 plus ramucirumab (IRIS1Rmab) as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: A multicenter phase II study in Japan (N-DOCC-F-C-1701)

被引：0
|
作者：
Kobayashi, K. [1 ]
Morita, M. [1 ]
Ito, S. [1 ]
Inoue, Y. [1 ]
Yamaguchi, I. [1 ]
Kosaka, T. [1 ]
Kuba, S. [1 ]
Sakimura, C. [1 ]
Soyama, A. [1 ]
Adachi, T. [1 ]
Ohno, S. [1 ]
Kobayashi, S. [1 ]
Hara, T. [1 ]
Hidaka, M. [1 ]
Hayashida, N. [1 ]
Yamanouchi, K. [1 ]
Kanetaka, K. [1 ]
Takatsuki, M. [1 ]
Eguchi, S. [1 ]
机构：
[1] Nagasaki Univ, Grad Sch Biomed Sci, Dept Surg, Nagasaki, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
192TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [41] S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis
    Kim, S. Y.
    Hong, Y. S.
    Shim, E. K.
    Kong, S-Y
    Shin, A.
    Baek, J. Y.
    Jung, K. H.
    BRITISH JOURNAL OF CANCER, 2013, 109 (06) : 1420 - 1427
  • [42] Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer
    Yamada, Y.
    Tahara, M.
    Miya, T.
    Satoh, T.
    Shirao, K.
    Shimada, Y.
    Ohtsu, A.
    Sasaki, Y.
    Tanigawara, Y.
    BRITISH JOURNAL OF CANCER, 2008, 98 (06) : 1034 - 1038
  • [43] Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer
    Y Yamada
    M Tahara
    T Miya
    T Satoh
    K Shirao
    Y Shimada
    A Ohtsu
    Y Sasaki
    Y Tanigawara
    British Journal of Cancer, 2008, 98 : 1034 - 1038
  • [44] Second line chemotherapy with irinotecan (CPT-11) and mitomycin-C (MMC) in patients with advanced/metastatic colorectal (CC) and gastric cancer (GC): A phase II trial.
    Papamichael, D
    Bamias, A
    Ioannides, G
    Syrigos, K
    Demosthenous, C
    Pavlidis, N
    ANNALS OF ONCOLOGY, 2000, 11 : 57 - 57
  • [45] A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
    Lee, Keun-Wook
    Kim, Bum Jun
    Kim, Mi-Jung
    Han, Hye Sook
    Kim, Jin Won
    Park, Young Lee
    Park, Sook Ryun
    CANCER RESEARCH AND TREATMENT, 2017, 49 (03): : 706 - 716
  • [46] A multicenter randomized phase II study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus either S-1 or capecitabine
    Kim, B.
    Lee, K. W.
    Kim, M. J.
    Han, H. S.
    Park, Y. L.
    Park, S. R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S432 - S432
  • [47] Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy
    Hong, Yong Sang
    Lee, Jeeyun
    Kim, Kyu-pyo
    Lee, Jae-Lyun
    Park, Young Suk
    Park, Joon Oh
    Park, Se Hoon
    Kim, Sun Young
    Baek, Ji Yeon
    Kim, Jee Hyun
    Lee, Keun-Wook
    Kim, Tae-You
    Kim, Tae Won
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 183 - 191
  • [48] Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy
    Yong Sang Hong
    Jeeyun Lee
    Kyu-pyo Kim
    Jae-Lyun Lee
    Young Suk Park
    Joon Oh Park
    Se Hoon Park
    Sun Young Kim
    Ji Yeon Baek
    Jee Hyun Kim
    Keun-Wook Lee
    Tae-You Kim
    Tae Won Kim
    Investigational New Drugs, 2013, 31 : 183 - 191
  • [49] A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China
    Xiao, Cheng
    Qian, Jiong
    Zheng, Yulong
    Song, Fang
    Wang, Qiangfeng
    Jiang, Haiping
    Mao, Chenyu
    Xu, Nong
    MEDICINE, 2019, 98 (20)
  • [50] A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy for colorectal cancer: The AIRS study
    Honda, M.
    Matsuda, C.
    Tanaka, C.
    Kondo, K.
    Takahashi, T.
    Kosugi, C.
    Tokunaga, Y.
    Takemoto, H.
    Kim, H. M.
    Sakamoto, J.
    Oba, K.
    Mishima, H.
    ANNALS OF ONCOLOGY, 2018, 29 : 161 - 161
12345